Thabata Caroline da Rocha Siqueira1, Carolina Fischinger Moura de Souza2, Paulo Lompa3, Mercedes Picarelli4, Ilóite Scheibel5, Fernanda Bender2, Régis Guidobono2, Maira Graeff Burin2, Roberto Giugliani6,7,8. 1. Postgraduate Program in Child and Adolescent Health, UFRGS, Porto Alegre, RS, Brazil. 2. Medical Genetics Service, Hospital de Clinicas de Porto Alegre, Porto Alegre, RS, Brazil. 3. Orthopedics and Traumatology Service, Hospital de Clinicas de Porto Alegre, Porto Alegre, RS, Brazil. 4. Hospital São Lucas, PUCRS, Porto Alegre, RS, Brazil. 5. Grupo Hospitalar Conceição, Porto Alegre, RS, Brazil. 6. Postgraduate Program in Child and Adolescent Health, UFRGS, Porto Alegre, RS, Brazil. rgiugliani@hcpa.edu.br. 7. Medical Genetics Service, Hospital de Clinicas de Porto Alegre, Porto Alegre, RS, Brazil. rgiugliani@hcpa.edu.br. 8. Department of Genetics, UFRGS, Porto Alegre, RS, Brazil. rgiugliani@hcpa.edu.br.
Abstract
INTRODUCTION: The mucopolysaccharidoses (MPS) are a group of 11 inborn errors of metabolism (IEM) which are part of the lysosomal storage diseases (LSDs). The MPS are multisystemic conditions that affect the entire body, with variations in the clinical presentation, having specific treatments available depending on the type of MPS. Nearly all MPS disorders compromise the osteoarticular system in different ways, and virtually all patients have abnormal urinary excretion of glycosaminoglycans (GAGs). MPS are rare diseases that are underdiagnosed due to health-care professionals' lack of awareness, to poor access to screening and diagnostic methods, and to their extensive clinical heterogeneity. Attenuated forms may occur, which can make diagnosis of MPS even more difficult. METHODS: This study was conducted prospectively from March 2012 to January 2014 and included 55 patients at rheumatology and/or orthopedic services in Porto Alegre, Brazil. The screened patients presented with articular manifestations with no defined etiology. These patients were screened by quantitative and qualitative assessment of urinary GAGs. RESULTS AND DISCUSSION: Among the 55 cases investigated, one 15-year-old patient exhibited increased urinary GAG excretion; this patient was subsequently diagnosed with an attenuated form of MPS II, which was previously undetected. CONCLUSION: Although the proportion of patients with MPS identified in the study sample was small (1/55), this study shows that these diseases are underdiagnosed and that systematic screening can help identify patients who may benefit from specific treatments already available for several MPS types.
INTRODUCTION: The mucopolysaccharidoses (MPS) are a group of 11 inborn errors of metabolism (IEM) which are part of the lysosomal storage diseases (LSDs). The MPS are multisystemic conditions that affect the entire body, with variations in the clinical presentation, having specific treatments available depending on the type of MPS. Nearly all MPS disorders compromise the osteoarticular system in different ways, and virtually all patients have abnormal urinary excretion of glycosaminoglycans (GAGs). MPS are rare diseases that are underdiagnosed due to health-care professionals' lack of awareness, to poor access to screening and diagnostic methods, and to their extensive clinical heterogeneity. Attenuated forms may occur, which can make diagnosis of MPS even more difficult. METHODS: This study was conducted prospectively from March 2012 to January 2014 and included 55 patients at rheumatology and/or orthopedic services in Porto Alegre, Brazil. The screened patients presented with articular manifestations with no defined etiology. These patients were screened by quantitative and qualitative assessment of urinary GAGs. RESULTS AND DISCUSSION: Among the 55 cases investigated, one 15-year-old patient exhibited increased urinary GAG excretion; this patient was subsequently diagnosed with an attenuated form of MPS II, which was previously undetected. CONCLUSION: Although the proportion of patients with MPS identified in the study sample was small (1/55), this study shows that these diseases are underdiagnosed and that systematic screening can help identify patients who may benefit from specific treatments already available for several MPS types.
Authors: B J Poorthuis; R A Wevers; W J Kleijer; J E Groener; J G de Jong; S van Weely; K E Niezen-Koning; O P van Diggelen Journal: Hum Genet Date: 1999 Jul-Aug Impact factor: 4.132